Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03592264 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
A Phase 1 study, sponsored by OBI Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT03592264: Clinical Trial Phase 1 study, sponsored by OBI Pharma.
NCT03592264 is a Phase 1 study that was terminated before completion, run by OBI Pharma. The registered enrollment target is 68 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (13% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03592264, a Phase 1 study, was terminated before completion, sponsored by OBI Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of OBI-3424 administered as a single agent.
Primary Outcome
Adverse events will be graded according to the Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0.
Interventions
- DRUG OBI-3424
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2018-07-02 |
| Est. Completion | 2024-03-21 |
| Phase | Phase 1 |
Why NCT03592264 stopped before completion
NCT03592264 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (13% higher).
The record links to 0 conditions, and to 1 intervention - of which OBI-3424 is the first listed.
NCT03592264 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03592264 about?
NCT03592264 is a clinical study titled "A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors". A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of OBI-3424 administered as a single agent.
What is the current status of trial NCT03592264?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2018-07-02. Estimated completion is 2024-03-21.
What interventions are being tested in trial NCT03592264?
The interventions under investigation include: OBI-3424 (DRUG).
Who is sponsoring clinical trial NCT03592264?
This trial is sponsored by OBI Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03592264's enrollment target sits among peer trials
68 776th of 2000 higher than 1,219 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI